Shanghai Xinpu Biomedical Technology

Simp-Bio (Shanghai Xinpu Biomedical Technology) is a biopharmaceutical company focused on the development of innovative targeted protein degradation (TPD) therapies, including PROTACs and molecular glues. The company leverages its proprietary platform to design small molecules that harness the body's natural protein disposal system to eliminate disease-causing proteins that are otherwise difficult to target. Simp-Bio's pipeline primarily targets oncology and autoimmune diseases, with a focus on hormone-driven cancers and hematological malignancies. By optimizing the E3 ligase recruitment and linker chemistry, the company aims to develop highly selective and potent degraders with improved oral bioavailability and safety profiles.